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Community-acquired urinary tract infection (UTI) 
is a common medical condition affecting up to 
20% of women sometime in their lifetime. These 
infections are usually diagnosed in previously healthy 
women with no underlying disease or anatomical 
anomalies.[1] Several risk factors have been described in the literature: 
(i) frequent sexual intercourse; (ii) lack of urination after sexual 
intercourse; (iii) a new sexual partner in the past year; (iv) use of a 
diaphragm or spermicide; (v) a history of recurrent UTI, and (vi) the 
occurrence of UTI in a first-degree female relative.[1,2]
Escherichia coli is the most common community-acquired UTI 
pathogen and is responsible for 75 - 95% of cases.[1] The remaining 
infections are usually caused by Gram-negative Enterobacteriaceae 
or Gram-positive cocci (GPC).[1] The extensive use of antimicrobial 
agents to treat community-acquired UTIs has resulted in the 
emergence of antimicrobial resistance among some of these bacterial 
species, particularly in developing countries.[3,4] Of current concern is 
the increased prevalence of community-acquired extended-spectrum 
β-lactamase (ESBL)-producing organisms.[5] 
Since recent aetiological and antimicrobial susceptibility data 
relating to community-acquired UTIs within South Africa (SA) are 
scarce, we undertook such a survey among women attending public 
and private healthcare facilities in Gauteng Province.
Methods
Study design
We conducted a multi-centre cross-sectional study to determine 
the prevalence and antimicrobial-resistance profile of bacteria 
causing community-acquired UTIs in women. We enrolled sufficient 
symptomatic women to achieve a recruitment target of 200 women 
with microbiologically confirmed UTIs. The study took place 
in Gauteng Province at 1 public primary healthcare site and 5 
private practitioners’ clinics between March and November 2011. 
Participation took place on the day of study enrolment and no 
Antimicrobial susceptibility of organisms causing 
community-acquired urinary tract infections 
in Gauteng Province, South Africa
D A Lewis,1,2,3 FRCP (UK), PhD; L Y E Gumede,1 N Dip M Tech; L A van der Hoven,4 MB ChB; G N de Gita,1 MSc (Stats); E J E de Kock,5  
Dip Pharm; T de Lange6; V Maseko,1 B Tech; V Kekana,1 RN (PHC); F P Smuts,4 BSc (Hons); O Perovic,7,8 FCPath (Micro) SA, MMed 
1  Centre for HIV and Sexually Transmitted Infections, National Institute for Communicable Diseases, National Health Laboratory Service, 
Johannesburg, South Africa
2  Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
3  Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa
4  Merck, Johannesburg, South Africa
5  Retrasol Research and Training Solutions, Pretoria, South Africa
6  DamaneX, Centurion, South Africa
7  Centre for Opportunistic, Tropical and Hospital Infections, National Institute for Communicable Diseases, National Health Laboratory Service, 
Johannesburg, South Africa
8  Department of Clinical Microbiology and Infectious Diseases, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South 
Africa
Corresponding author: D A Lewis (davidl@nicd.ac.za)
Background. Patients with community-acquired urinary tract infections (UTIs) frequently present to healthcare facilities in South Africa (SA).
Aim. To provide information on UTI aetiology and antimicrobial susceptibility of pathogens.
Methods. We recruited women with UTI-related symptoms, who tested positive for ≥2 urine dipstick criteria (proteinuria, blood, leucocytes 
or nitrites) at 1 public and 5 private primary healthcare facilities in 2011. Demographic and clinical data were recorded and mid-stream 
urine (MSU) specimens were cultured. UTI pathogens were Gram-stained and identified to species level. Etest-based antimicrobial 
susceptibility testing was performed for amoxicillin/clavulanic acid, cefixime, cefuroxime, ciprofloxacin, fosfomycin, levofloxacin, 
nitrofurantoin, norfloxacin and trimethoprim/sulphamethoxazole.
Results. Of the 460 women recruited, 425 MSU samples were processed and 204 UTI pathogens were identified in 201 samples. Most 
pathogens were Gram-negative bacilli (GNB) (182; 89.2%) and 22 (10.8%) were Gram-positive cocci (GPC). Escherichia coli was the most 
frequent GNB (160; 79.6%), while Enterococcus faecalis was the predominant GPC (8; 4.0%). The UTI pathogens had similar susceptibility 
profiles for fosfomycin (95.5%; 95% confidence interval (CI) 92.6 - 98.4), the 3 fluoroquinolones (94.1%; 95% CI 90.8 - 97.4), nitrofurantoin 
(91.7%; 95% CI 87.8 - 95.6), cefuroxime (90.1%; 95% CI 86.0 - 94.3) and cefixime (88.2%; 95% CI 83.7 - 92.6). UTI pathogens were less 
susceptible to amoxicillin/clavulanic acid (82.8%; 95% CI 77.5 - 88.0) when compared with fluoroquinolones and fosfomycin. Trimethoprim/
sulphamethoxazole was the least efficacious antimicrobial agent (44.3% susceptible; 95% CI 37.4 - 51.2).
Conclusion. This study provides relevant data for the empirical treatment of community-acquired UTIs in SA.
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follow-up visits were required. The study was approved by the 
Human Research Ethics Committee (Medical) of the University of 
the Witwatersrand (M101119) and Pharma Ethics.
Participant screening and enrolment
The women, aged 18 - 80 years were screened by urinalysis. Eligibility 
criteria included: (i) presenting with UTI symptoms, and (ii) the 
provision of informed written consent. Exclusion criteria included 
women with a history of current renal disease or known urinary 
tract abnormalities, as well as recent in-patient hospitalisation or the 
use of antimicrobial agents within the previous month. We enrolled 
women if their mid-stream urine (MSU) was positive for ≥2/4 criteria 
(protein, blood, leucocytes or nitrites); using either Quick Profile 
urine reagent strips (LumiQuick Diagnostics, USA) or the Uryxxon 
Relax automated urinalysis system (Macherey-Nagel, Germany). 
Treatment of participants
We treated women attending the public clinic according to Essential 
Drugs List (EDL) recommendations with either a single 500 mg dose 
of ciprofloxacin (for non-pregnant participants) or with a 1-week 
course of 250 mg amoxicillin/125 mg clavulanic acid given 8-hourly 
(for pregnant participants).[6] We examined women attending private 
clinics and treated them according to their practitioner’s antibiotic 
preference. We recorded the antimicrobial agents used to treat the 
presumptive UTIs on a laboratory tracker form that accompanied 
the MSU sample to the laboratory. Clinicians received antimicrobial 
susceptibility results only for those cases in which a urinary pathogen 
was isolated and determined to be resistant to the dispensed 
antimicrobial agent. 
Bacterial isolation, species identification and laboratory 
reporting criteria
MSU specimens were sent in a cooler box to the National Institute 
for Communicable Diseases (NICD). We discarded MSU specimens 
that were >24 hours old on arrival at the NICD. Urine specimens were 
processed according to a routine standard operative procedure by using 
a 1  μl loop to inoculate both 5% blood and MacConkey agar plates 
(Diagnostic Media Products, SA). Inoculated plates were incubated 
for 18 hours at 35 - 37oC and then inspected for bacterial growth. We 
regarded the presence of ≥10 identical colonial morphotypes (≥104 
colony-forming units (CFU)/ml) as microbiological evidence of a UTI. 
If <10 bacterial colonies were present, the urine was reported to have 
‘no significant growth’. If 2 different bacterial colony types were present 
in equal numbers, both were purified for further laboratory work. If 
≥3 bacterial colony types were present, then the urine was reported 
as ‘mixed growth’ and the plates were discarded. The predominant 
colonies were re-cultured on 5% blood agar prior to identification and 
antimicrobial susceptibility testing. Bacterial colonies were initially 
classified by Gram-stain morphology and subsequently definitively 
identified using the VITEK 2 system (bioMérieux SA, France). 
Bacterial strains were archived at -70oC in Microbank storage vials 
(Pro-Lab Diagnostics, Canada) for the study duration. 
Antimicrobial susceptibility testing
Bacterial species were first suspended in 2 ml 0.9% sterile saline 
to turbidity equivalent to a 0.5 McFarland standard (108 CFU/ml). 
A cotton-tipped swab was used to inoculate appropriate media 
(Diagnostics Media Products, SA) with the bacterial suspension. 
As recommended by the Clinical Laboratory Standards Institute 
(CLSI), we used Mueller-Hinton agar to perform antimicrobial 
susceptibility testing for either Gram-negative bacilli (GNB) or 
GPC in clusters, while Mueller-Hinton agar with 5% sheep’s blood 
was used for GPC in chains.[7] Susceptibility to the following 
antimicrobial agents was determined immediately after pathogen 
identification using Etest strips (AB Biodisk, Sweden): cefixime, 
cefuroxime, ciprofloxacin, norfloxacin, levofloxacin, amoxicillin/
clavulanic acid and trimethoprim/sulphamethoxazole. After 
recruitment had been completed, we performed additional Etest-
based minimum inhibitory concentration (MIC) assays for 2 further 
antimicrobial agents, fosfomycin and nitrofurantoin, using bacterial 
isolates cultured from -70oC stock vials in the same manner as 
described above. For fosfomycin, glucose-6-phosphate (25 mg/l) 
was incorporated into the Mueller-Hinton agar, as recommended 
by CLSI guidelines.[7] We used 3 bacterial strains as controls for 
antimicrobial susceptibility testing: E. coli (American Type Culture 
Collection (ATCC) 25922); Staphylococcus aureus (ATCC 25923); 
Streptococcus pneumoniae (ATCC 49619). After placing Etest strips 
on the inoculated agar surface, we incubated plates for 24 hours 
before reading the MIC of each antimicrobial agent for each isolate, 
according to manufacturer’s instructions. 
Wherever possible, we interpreted MICs according to CLSI 
breakpoint criteria.[7] As surrogate antibiotics for cefixime we used the 
CLSI breakpoints for the parenteral third-generation cephalosporins, 
ceftizoxime and ceftriaxone, for GPC in clusters and for β-haemolytic 
streptococci, respectively. Since enterococci are inherently non-
susceptible to cephalosporins, they were reported as such, regardless of 
MIC value. For β-haemolytic streptococci we reported: (i) susceptibility 
to amoxicillin/clavulanic acid using surrogate CLSI breakpoints for 
ampicillin; (ii) susceptibility to cefuroxime using surrogate CLSI 
breakpoints for ceftriaxone; and (iii) susceptibility to trimethoprim/
sulphamethoxazole using surrogate CLSI breakpoints for S. pneumoniae. 
When testing fosfomycin against GPC, we used the antimicrobial 
susceptibility breakpoints of the British Society for Antimicrobial 
Chemotherapy (BSAC) for staphylococci (version 10.2, May 2011) for 
both GPC in clusters and β-haemolytic streptococci.[8] We also used 
the BSAC breakpoints to determine susceptibility of β-haemolytic 
streptococci to nitrofurantoin.
Data analysis
Data were entered into a Microsoft Access database and analysed 
using Microsoft Excel. We determined the MIC50 and MIC90 values 
for each antimicrobial agent and investigated associations between 
variables of interest using the chi-squared test. All statistical analyses 
were conducted using STATA version 10.1 (StataCorp, USA).
Results
Participant recruitment and characteristics
Overall, 460 participants were recruited at the 1 public (n=230) and 
the 5 private practice facilities (n=230). The mean participant age was 
lower at the public sector facility (31.0 v. 34.7 years). The age range of 
recruited participants did not differ markedly by facility type (18 - 74 
v. 18 - 79 years in public and private sector, respectively). Almost all 
participants attending the public facility were black Africans (229; 
99.6%), while the racial distribution was more varied at the private 
practice facilities (139 white (60.4%); 56 black African (24.3%); 21 
Indian (9.1%); 10 coloured (4.3%); 4 unknown (1.7%)). 
Urinalysis and clinical symptoms
The frequency distribution of detected urine dipstick abnormalities 
and UTI-related clinical symptoms is shown in Table 1. Isolation 
of a UTI pathogen was significantly associated with proteinuria 
(p=0.008), the presence of nitrites (p<0.001), dysuria (p<0.001), 
urgency (p<0.001), frequency (p<0.001) and strong-smelling urine 
(p<0.001). In contrast, failure to isolate a bacterial pathogen was 
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significantly associated with discoloured 
urine (p=0.037) and pregnancy (p<0.001). 
There were no other significant associations 
between UTI pathogen isolation and the 
other diagnostic criteria listed in Table 1.
Antimicrobial agent prescribing 
practice 
At the public facility, ciprofloxacin (192; 
83.5%) and amoxicillin/clavulanic acid (19; 
8.5%) were the main antimicrobial agents 
prescribed to participants in accordance 
with the EDL guideline. The study nurse 
reported drug stock-out at the facility’s 
pharmacy on some days during the study; 
accordingly, other drugs had to be used to 
treat presumptive UTIs in the remaining 19 
(8.3%) cases. Antimicrobial prescribing was 
more varied at the private practice facilities 
for the 151 (65.7%) participants for whom 
data were recorded. Ciprofloxacin was 
the most frequent therapeutic choice (76; 
50.3%), followed by fosfomycin (27; 17.9%), 
amoxicillin/clavulanic acid (23; 15.2%), 
cefuroxime (10; 6.6%), cefpodoxime (7; 
4.6%), levofloxacin (6; 4.0%) and amoxicillin 
(2; 1.3%).
Laboratory culture and identification 
of UTI pathogens
Within the laboratory we processed 425 
(92.4%) MSU samples; 35 (7.6%) specimens 
were discarded on the basis of being >24 
hours old. We isolated bacteria in significant 
numbers in 203 (47.8%) participants; most 
were single organisms (200; 98.5%) while 3 
participants (1.5%) had 2 different bacterial 
species identified. Culture of the MSU samples 
of 2 patients grew Gram-positive bacteria, 
Kocuria kristinae and Pediococcus pentosaceus, 
that we regarded as skin and vaginal 
commensals rather than UTI pathogens. 
Accordingly, we did not include these 2 
isolates in the antimicrobial susceptibility 
analyses. Plates with ‘no significant growth’, 
‘no growth’ or ‘mixed growth’ were reported 
for 138 (32.2%), 84 (19.6%) and 0 (0.0%) 
participants, respectively. 
After excluding the 2 commensal isolates 
described above, we identified a total of 204 
UTI pathogens in 201 participants (Table 
2). In terms of Gram-stain morphotype, 182 
(89.2%) were GNB and 22 (10.8%) were GPC 
(Table 2). Self-reported pregnancy status 
was available for most of these participants 
(199/201, 99.0%). The prevalence of GPC 
was significantly higher among pregnant 
than non-pregnant women (5/19 (26.3%) v. 
17/180 (9.4%), respectively; p=0.026). There 
were no significant associations between the 
detection of a UTI pathogen or the Gram 
stain morphotype and either the participant’s 
racial group (p=0.448 and p=0.734, 
respectively) or the facility type (p=0.944 
and p=0.456, respectively). Identification 
of the UTI pathogens-to-species level, 
as determined by the VITEK 2 system, 
demonstrated that E. coli accounted for just 
over three-quarters of all UTI pathogens 
isolated (160; 79.6%), while E. faecalis was 
the most frequent Gram-positive organism 
detected (8; 4.0%) (Table 2). There was a 











Lower abdominal pain 336 (79.1)
Dysuria 324 (76.2)
Frequency of micturition 220 (51.8)
Discoloured urine 160 (37.7)
Cloudy urine 148 (34.8)
Urgency 138 (32.5)
Strong smell to urine 124 (29.2)
Loin or upper back pain 69 (12.2)
Nausea and/or vomiting 45 (10.6)
Chills or fevers 28 (6.6)
Table 2. Frequency of the community-acquired UTI pathogens (N=204) isolated 
from patients (N=201) by Gram stain morphotype and facility type
UTI pathogens*










GNB (n=182)      
E. coli 83 (77.6) 77 (81.9) 160 (79.6)
Proteus mirabilis 6 (5.6) 4 (4.3) 10 (5.0)
Citrobacter koseri - 1 (1.1) 1 (0.5)
Klebsiella pneumoniae 4 (3.7) 1 (1.1) 5 (2.5)
Leclercia adecarboxylata - 1 (1.1) 1 (0.5)
Enterobacter aerogenes 3 (2.8) - 3 (1.5)
Salmonella spp. 1 (0.9) - 1 (0.5)
Unidentified† 1 (0.9) - 1 (0.5)
GPC (n=22)    
E. faecalis 1 (0.9) 7 (7.4) 8 (4.0)
Staphylococcus saprophyticus 3 (2.8) 2 (2.1) 5 (2.5)
Streptococcus agalactiae 5 (4.7) 2 (2.1) 7 (3.5)
Staphylococcus haemolyticus 1 (0.9) 1 (1.1) 2 (1.0)
GNB = Gram-negative bacilli; GPC = Gram-positive cocci.
* Excludes 1 K. kristinae isolate and 1 P. pentosaceus isolate, which were regarded as commensal contaminants from the skin 
and vagina, respectively. 
† One plate, containing a GNB, was discarded in error before species identification and antimicrobial susceptibility testing. 
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significantly higher prevalence of E. faecalis isolation in MSU samples 
collected in the private facilities than in the public facility (7/94 (7.4%) 
v. 1/107 (0.9%), respectively; p=0.018). 
Antimicrobial susceptibility
In error, we discarded 1 UTI pathogen, a GNB, prior to 
antimicrobial susceptibility testing. Table 3 shows the susceptibility 
of the remaining 203 UTI pathogens to the 9 antimicrobial 
agents tested, as well as the GNB-related MIC50 and MIC90 values 
for each antimicrobial agent. A few of the bacterial isolates 
were not available for post-recruitment susceptibility testing with 
fosfomycin (2 isolates) and nitrofurantoin (10 isolates). Overall, the 
UTI pathogens were most susceptible to fosfomycin (95.5%; 95% 
confidence interval (CI) 92.6 - 98.4), the 3 fluoroquinolones (94.1%; 
95% CI 90.8 - 97.4), nitrofurantoin (91.7%; 95% CI 87.8 - 95.6), 
cefuroxime (90.1%; 95% CI 86.0 - 94.3) and cefixime (88.2%; 95% 
CI 83.7 - 92.6). The performance of these 7 antimicrobial agents 
was regarded as similar based on overlapping 95% CIs. Although 
the UTI pathogens were less susceptible to amoxicillin/clavulanic 
acid (82.8%; 95% CI 77.5 - 88.0) than to fluoroquinolones and 
fosfomycin; amoxicillin/clavulanic acid had a similar susceptibility 
profile to cefuroxime, cefixime and nitrofurantoin. Trimethoprim/
sulphamethoxazole was the least efficacious antimicrobial agent 
(44.3% susceptibility; 95% CI 37.4 - 51.2).
Discussion
This study describes the aetiology of community-acquired UTIs 
in women presenting to public and private facilities in Gauteng 
Province. In keeping with the existing literature, most bacterial 
isolates were GNB including E. coli, which accounted for 80% of 
bacterial isolates.[1] The UTI pathogens tested were most susceptible 
to fluoroquinolones, cephalosporins, fosfomycin and nitrofurantoin. 
While these pathogens were less susceptible to amoxicillin/clavulanic 
acid than to fluoroquinolones and fosfomycin, amoxicillin/clavulanic 
acid had a similar susceptibility profile to both cephalosporins and 
nitrofurantoin. In contrast, >50% of the UTI pathogens tested 
were susceptible to trimethoprim/sulphamethoxazole. In terms of 
directed therapy based on known Gram-stain morphotypes, our 
data suggest that fosfomycin, fluoroquinolones and cephalosporins 
would be good choices for GNB infections while GPC infections 
may be treated best with amoxicillin/clavulanic acid, nitrofurantoin 
or fluoroquinolones. 
Community-acquired UTIs continue to represent a financial 
burden for many countries and short-course treatments are 
favoured, where possible, as resistance develops less commonly. [9] 
As antimicrobial resistance escalates, the cost of managing such 
infections will increase as more expensive antimicrobial agents 
are required to ensure microbiological cure. Within SA, most 
community-acquired UTIs are treated empirically without the need 
for laboratory investigation and susceptibility testing of isolated UTI 
pathogens. The lack of community-derived microbiological data 
presents challenges to those responsible for recommending first-
line UTI therapy/ies. The choice of first-line antimicrobial agents is 
determined by a number of factors, including in vitro susceptibility, 
side-effect profile, patient allergy, patient’s compliance profile, 
financial cost to the healthcare system or the patient, therapeutic 
efficacy, and the agent’s propensity for producing an ecological 
adverse effect, i.e. the development of further bacterial antimicrobial 
resistance over time due to selection pressure.[10] 
Maartens and Oliver[11] undertook a similar microbiological study 
of community-acquired UTI pathogens to determine the prevalence 
of antimicrobial resistance in Cape Town, SA. Their study, performed 
over a decade ago with different methodology, reported an almost 
identical prevalence of resistance to trimethoprim/sulphamethoxazole 
(47.3%), but a relatively low level of resistance to ciprofloxacin 
(2.8%). Our data confirm the rising prevalence of fluoroquinolone 
resistance among community-acquired UTI pathogens in SA.[12] The 
Infectious Diseases Society of America (IDSA) recently published 
guidelines that recommend a 10% resistance threshold for the 
treatment of community-acquired UTIs with fluoroquinolones; 
above this threshold, fluoroquinolones should not be used as 
empirical treatment.[13] Fluoroquinolones offer broad-spectrum 
UTI pathogen cover with few side-effects and are suitable for the 
treatment of complicated UTI and pyelonephritis; however, their 
main disadvantages are that they are contraindicated in pregnancy 
and they have a high propensity for ecological adverse effects.[1]









Susceptibility MIC50 MIC90 Susceptibility Susceptibility
n % (95% CI) (mg/l) (mg/l) n % (95% CI) n % (95% CI)
Ciprofloxacin 170 93.9 (90.4 - 97.4) 0.012 0.19 21 95.5 (86.0 - 100.0) 191 94.1 (90.8 - 97.4)
Levofloxacin 170 93.9 (90.4 - 97.4) 0.023 0.38 21 95.5 (86.0 - 100.0) 191 94.1 (90.8 - 97.4)
Norfloxacin 170 93.9 (90.4 - 97.4) 0.064 0.75 21 95.5 (86.0 - 100.0) 191 94.1 (90.8 - 97.4)
Cefixime 172 95.0 (91.8 - 98.2) 0.25 0.75 7 31.8 (10.7 - 53.0) 179 88.2 (83.7 - 92.6)
Cefuroxime 169 93.4 (89.7 - 97.0) 3 4 14 63.6 (41.8 - 85.5) 183 90.1 (86.0 - 94.3)
Fosfomycin§ 176 98.3 (96.4 - 100.0) 0.5 4 16 72.7 (52.5 - 92.9) 195 95.5 (92.6 - 98.4)
Nitrofurantoin¶ 155 90.6 (86.2 - 95.1) 12 32 22 100.0 (100.0 - 100.0) 177 91.7 (87.8 - 95.6)
Amoxicillin/clavulanic acid 146 80.7 (74.9 - 86.5) 6 16 22 100.0 (100.0 - 100.0) 168 82.8 (77.5 - 88.0)
Trimethoprim/sulphamethoxazole 75 41.4 (34.2 - 48.7) >32 >32 15 68.2 (47.0 - 89.3) 90 44.3 (37.4 - 51.2)
MIC = minimum inhibitory concentration; GNB = Gram-negative bacilli; GPC = Gram-positive cocci.
* One plate, containing a GNB, was discarded in error before species identification and antimicrobial susceptibility testing. 
† MIC50/MIC90 values are not presented for GPC due to the heterogeneous nature of this group.‡ Two isolates (K. kristinae, P. pentosaceus) were excluded from the antimicrobial susceptibility analysis as they were deemed to be commensal contaminants rather than true UTI pathogens.
§ Two Gram-negative strains (E. coli and P. mirabilis) were unavailable for fosfomycin susceptibility testing.
¶ Ten Gram-negative strains (E. coli (n=8) and P. mirabilis (n=2)) were unavailable for nitrofurantoin susceptibility testing.
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Fosfomycin has a broad antibacterial spectrum and inhibits 
phosphoenolpyruvate transferase, the first enzyme involved in 
peptidoglycan synthesis.[14] Like nitrofurantoin, fosfomycin is only 
suitable to treat lower UTIs. Administered as a single oral dose of 
3 g fosfomycin-trometamol, it has few side-effects and is safe in 
pregnancy, it does not exhibit cross-resistance and it is useful to 
treat multidrug-resistant UTI pathogens, including ESBL-producing 
Enterobacteriaceae and vancomycin-resistant enterococci.[14-16] A major 
disadvantage of fosfomycin is its relatively high cost in comparison 
with the other antimicrobial agents currently in use for the treatment 
of community-acquired UTIs. In terms of clinical efficacy, there 
are some concerns about unacceptably high prevalence of bacterial 
persistence. [17] Although fosfomycin resistance infrequently occurs as a 
result of chromosomal mutations, resistant bacteria exhibit a reduced 
rate of growth and appear less virulent in terms of their ability to 
adhere to uro-epithelial cells in vitro.[18]
Our data suggest that cephalosporins are best suited as a treatment 
option for directed therapy for confirmed Gram-negative UTIs. This 
differential susceptibility of cephalosporins on the basis of Gram-
stain morphotype has been described previously in SA.[10] Although 
cefixime, an oral third-generation cephalosporin, may be used as 
a single 400 mg dose for the treatment of UTI, it is presently only 
available for the treatment of gonorrhoea in the SA public sector. 
Oral cephalosporins have the advantage of being safe to prescribe in 
pregnancy and induce few side-effects. 
Nitrofurantoin monohydrate macrocrystalline formulation, given 
orally as a 5-day course, is well tolerated, has good efficacy and a 
low propensity for ecologically adverse events. Nitrofurantoin is 
recommended as one of several first-line agents in the IDSA 2010 
guidelines and, within SA, it is also recommended for short-term 
prophylaxis in women with recurrent UTIs. Nitrofurantoin may 
be either bacterio-static or -cidal in action, depending on the 
concentration and susceptibility of the infecting organism, and 
exerts its effects by inhibiting DNA, RNA, protein and cell wall 
synthesis. Side-effects are generally minor, such as nausea and urine 
discolouration, but haemolytic anaemia is a risk in those patients 
with glucose-6-phosphate dehydrogenase deficiency, and pulmonary 
fibrosis may occur with long-term use. 
A strength of our study is that it was undertaken at both public 
and private sector healthcare facilities in Gauteng Province; however, 
the findings may not be nationally representative. Additionally, 
to enhance organism yield, we selected participants after initial 
screening by urinalysis, which could present a bias in pathogen 
selection. For some of the antibiotics it was difficult to determine 
the category of antimicrobial susceptibility due to the absence of 
appropriate CLSI or BSAC MIC breakpoints. A further limitation 
is that we measured in vitro resistance rates; these data may over-
estimate clinically relevant resistance to the antimicrobial agents 
tested. Finally, although injectable gentamicin and ceftriaxone are 
recommended for the treatment of severe upper UTIs in the SA EDL, 
they were not tested in the current study.
In conclusion, our study provides valuable local data for empirical 
antimicrobial therapy for community-acquired UTIs. In view of 
rising antimicrobial resistance trends among UTI pathogens, we 
recommend that consideration be given to the establishment of a 
national sentinel surveillance system to monitor the antimicrobial 
susceptibility profiles of community-acquired UTI pathogens within 
SA. Such a programme would generate the required evidence base to 
support antibiotic guideline and policy creation.
Acknowledgements. We thank Prof. H S Schoeman for the statistical study 
report he provided to Merck Serono at the end of the study and Dr A Brink 
for his insightful comments during protocol design and implementation 
of the study. We express our gratitude to the private practitioners who 
participated in the study: Drs W G Meyer and Y Steyn (Wierdamed); 
Drs C L Landman and M E Landman (Doctors CL & ME Landman Inc.); 
Drs A S Kilian, J C van Staden, J J Nienaber and P K Williams-Scott 
(Kilian, Nienaber and Associates); Drs Y Le Roux, J J Le Roux and H J 
Sommerville (Healthworx Centurion); and Dr P Steytler (Unitas Hospital, 
Centurion). We thank Mr L Maluleke for permission to undertake the 
study at Alexandra Health Centre, and the clinical and laboratory staff of 
the Centre for HIV and STIs for their assistance. 
Conflicts of interest. This study was sponsored by Merck, which is the 
manufacturer of cefixime. LvdH and FS were employed by Merck at the time 
of the study. EdK and TdL were contracted by Merck to assist with operational 
and data management aspects of the study, respectively. DL served as a 
voluntary member of the Merck Advisory Board during the time of the study. 
References
1. Hooton TM. Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 2012;366(11):1028-
1037. [http://dx.doi.org/10.1056/NEJMcp1104429]
2. Jancel T, Dudas V. Management of uncomplicated urinary tract infections. West J Med 2002;176(1):51-
55. [http://dx.doi.org/10.1136/ewjm.176.1.51]
3. Lester SC, del Pilar Pla M, Wang F, Perez Schael I, Jiang H, O’Brien TF. The carriage of Escherichia 
coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin 
Pu, China. N Engl J Med 1990;323(5):285-289. [http://dx.doi.org/10.1056/NEJM199008023230501]
4. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006;119:S20-28. 
[http://dx.doi.org/10.1016/j.amjmed.2006.03.013]
5. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: An 
emerging public-health concern. Lancet Infect Dis 2008;8(3):159-166. [http://dx.doi.org/10.1016/
S1473-3099(08)70041-0] 
6. Essential Drugs Programme. Primary health care standard treatment guidelines and essential 
medicines list 2008. 4th ed. Pretoria: National Department of Health, 2008.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility 
Testing; Twenty-Second Informational Supplement M100-S22. Wayne, PA, USA: Clinical and 
Laboratory Standards Institute; January 2012. http://antimicrobianos.com.ar/ATB/wp-content/
uploads/2012/11/M100S22E.pdf (accessed 25 March 2013).
8. British Society for Antimicrobial Chemotherapy. BSAC methods for antimicrobial susceptibility 
testing. http://bsac.org.uk/wp-content/uploads/2012/02/Version-10.2-2011-final-May-20111.pdf 
(accessed 25 March 2013).
9. Leibovici L, Wysenbeek AJ. Single-dose antibiotic treatment for symptomatic urinary tract infections 
in women: a meta-analysis of randomized trials. Q J Med 1991;78(285):43-57. 
10. Bosch FJ, van Vuuren C, Joubert G. Antimicrobial resistance patterns in outpatient urinary tract 
infections - the constant need to revise prescribing habits. S Afr Med J 2011;101(5):328-331. 
11. Maartens G, Oliver SP. Antibiotic resistance in community-acquired urinary tract infections. S Afr 
Med J 1994;84:600-602. 
12. Habte TM, Dube S, Ismail N, Hoosen AA. Hospital and community isolates of uropathogens at a 
tertiary hospital in South Africa. S Afr Med J 2009;99(8):584-587. 
13. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of 
acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases 
Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 
2011;52(5):e103-120. [http://dx.doi.org/10.1093/cid/ciq257]
14. Raz R. Fosfomycin: an old-new antibiotic. Clin Microbiol Infect 2011;18(1):4-7. [http://dx.doi.
org/10.1111/j.1469-0691.2011.03636.x]
15. Allerberger F, Klare I. In-vitro activity of fosfomycin against vancomycin-resistant enterococci. J 
Antimicrob Chemother 1999;43(2):211-217. [http://dx.doi.org/10.1093/jac/43.2.211]
16. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of 
multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae 
infections: a systematic review. Lancet Infect Dis 2010;10(1):43-50. [http://dx.doi.org/10.1016/S1473-
3099(09)70325-1]
17. Minassian MA, Lewis DA, Chattopadhyay D, Bovill B, Duckworth GJ, Williams JD. A comparison 
between single-dose fosfomycin trometamol (Monuril) and a 5-day course of trimethoprim in 
the treatment of uncomplicated lower urinary tract infection in women. Int J Antimicrob Agents 
1998;10(1):39-47. [http://dx.doi.org/10.1016/S0924-8579(98)00021-1]
18. Marchese A, Gualco L, Debbia EA, Schito GC, Schito AM. In vitro activity of fosfomycin against gram-
negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 
2003;22:53-59. [http://dx.doi.org/10.1016/S0924-8579(03)00230-9]
Accepted 4 April 2013.
